A phase 2 randomized study of an oral dual TORC1/2 inhibitor alone the dual TORC1/2 inhibitor and an oral PI3Ka inhibitor in combination weekly paclitaxel alone or the combination of weekly paclitaxel and PI3Ka inhibitor in women with advanced recurrent or persistent endometrial cancer
Brief description of study
If you have been diagnosed with endometrial cancer and have undergone prior platinum-based chemotherapy, you may qualify for this phase II study. The goal of this study is to see the safety and effectiveness of the investigational drugs MLN0128 and MLN1117 when given either as alone or in combination with paclitaxel, or when given in combination with each other (MLN0128 and MLN1117).
Clinical Study Identifier: s16-01251
ClinicalTrials.gov Identifier: NCTs16-01251
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.